{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Head+and+Neck+Squamous+Cell+Carcinoma&page=11",
    "query": {
      "condition": "Recurrent Head and Neck Squamous Cell Carcinoma",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 479,
    "total_pages": 48,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Head+and+Neck+Squamous+Cell+Carcinoma&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Head+and+Neck+Squamous+Cell+Carcinoma&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T05:29:57.820Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01846091",
      "title": "Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Estrogen Receptor Negative",
        "Estrogen Receptor Positive",
        "Head and Neck Squamous Cell Carcinoma",
        "HER2/Neu Negative",
        "HER2/Neu Positive",
        "Invasive Breast Carcinoma",
        "Progesterone Receptor Negative",
        "Progesterone Receptor Positive",
        "Recurrent Head and Neck Carcinoma",
        "Stage IV Breast Cancer",
        "Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2013-04-09",
      "completion_date": "2019-11-26",
      "has_results": false,
      "last_update_posted_date": "2023-02-14",
      "last_synced_at": "2026-10-14T05:29:57.820Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01846091"
    },
    {
      "nct_id": "NCT04634825",
      "title": "Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "Head and Neck Neoplasms",
        "Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Enoblituzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Retifanlimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tebotelimab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MacroGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2021-03-17",
      "completion_date": "2022-07-29",
      "has_results": true,
      "last_update_posted_date": "2023-12-20",
      "last_synced_at": "2026-10-14T05:29:57.820Z",
      "location_count": 6,
      "location_summary": "Baltimore, Maryland • Ann Arbor, Michigan • Las Vegas, Nevada + 3 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04634825"
    },
    {
      "nct_id": "NCT04144517",
      "title": "A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of Head and Neck"
      ],
      "interventions": [
        {
          "name": "Nemvaleukin Alfa",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mural Oncology, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2020-02-05",
      "completion_date": "2022-01-07",
      "has_results": true,
      "last_update_posted_date": "2024-10-16",
      "last_synced_at": "2026-10-14T05:29:57.820Z",
      "location_count": 7,
      "location_summary": "Miami, Florida • Atlanta, Georgia • Minneapolis, Minnesota + 3 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04144517"
    },
    {
      "nct_id": "NCT03978689",
      "title": "A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "HPV Positive Oropharyngeal Squamous Cell Carcinoma",
        "HPV-Related Carcinoma"
      ],
      "interventions": [
        {
          "name": "CUE-101",
          "type": "DRUG"
        },
        {
          "name": "KEYTRUDA®, Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cue Biopharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2019-07-30",
      "completion_date": "2026-01-04",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-10-14T05:29:57.820Z",
      "location_count": 17,
      "location_summary": "Tucson, Arizona • Palo Alto, California • New Haven, Connecticut + 14 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03978689"
    },
    {
      "nct_id": "NCT00003443",
      "title": "Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "bryostatin 1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1998-07",
      "completion_date": "2001-05",
      "has_results": false,
      "last_update_posted_date": "2013-06-24",
      "last_synced_at": "2026-10-14T05:29:57.820Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003443"
    },
    {
      "nct_id": "NCT00509665",
      "title": "Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 18,
      "start_date": "2005-06",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2018-07-12",
      "last_synced_at": "2026-10-14T05:29:57.820Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00509665"
    },
    {
      "nct_id": "NCT02124707",
      "title": "Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "Squamous Cell Carcinoma of the Head and Neck"
      ],
      "interventions": [
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2014-06-16",
      "completion_date": "2019-10-01",
      "has_results": true,
      "last_update_posted_date": "2020-08-12",
      "last_synced_at": "2026-10-14T05:29:57.820Z",
      "location_count": 2,
      "location_summary": "Chapel Hill, North Carolina • Midlothian, Virginia",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Midlothian",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02124707"
    },
    {
      "nct_id": "NCT04326257",
      "title": "Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of the Head and Neck"
      ],
      "interventions": [
        {
          "name": "Nivolumab+Relatlimab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab+Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dan Zandberg",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2020-05-14",
      "completion_date": "2024-08-12",
      "has_results": true,
      "last_update_posted_date": "2026-01-08",
      "last_synced_at": "2026-10-14T05:29:57.820Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04326257"
    },
    {
      "nct_id": "NCT02955290",
      "title": "CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Head and Neck Squamous Cell Carcinoma",
        "Lung Non-Small Cell Carcinoma",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "PD-L1 Positive",
        "Recurrent Head and Neck Squamous Cell Carcinoma",
        "Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8",
        "Stage III Lung Cancer AJCC v8",
        "Stage IIIA Lung Cancer AJCC v8",
        "Stage IIIB Lung Cancer AJCC v8",
        "Stage IIIC Lung Cancer AJCC v8",
        "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVB Lung Cancer AJCC v8",
        "Unresectable Lung Non-Small Cell Carcinoma",
        "Advanced Squamous Non-Small Cell Lung Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2016-12-22",
      "completion_date": "2027-12-09",
      "has_results": false,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-10-14T05:29:57.820Z",
      "location_count": 5,
      "location_summary": "Indianapolis, Indiana • Buffalo, New York • Roslyn, New York + 2 more",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Roslyn",
          "state": "New York"
        },
        {
          "city": "West Islip",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02955290"
    },
    {
      "nct_id": "NCT02706691",
      "title": "BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "FGFR Gene Amplification",
        "FGFR1 Gene Amplification",
        "FGFR2 Gene Amplification",
        "FGFR2 Gene Mutation",
        "FGFR3 Gene Mutation",
        "Head and Neck Squamous Cell Carcinoma",
        "Human Papillomavirus Infection",
        "Recurrent Head and Neck Carcinoma",
        "Recurrent Nasopharynx Carcinoma",
        "Recurrent Oropharyngeal Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "BGJ398",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2018-06-01",
      "completion_date": "2019-02-11",
      "has_results": true,
      "last_update_posted_date": "2019-04-16",
      "last_synced_at": "2026-10-14T05:29:57.820Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02706691"
    }
  ]
}